On June 15, 2022, Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing multiple first-in-class and best-in-class approaches that enhance regulatory T cells (Tregs) function in vivo, including autologous and allogeneic Treg-derived exosome therapeutics, and novel biologics, announced the execution of an option agreement for exclusive worldwide rights to a novel and proprietary technology platform enabling exosome engineering from Carnegie Mellon University. The exclusive option agreement involves the intellectual property rights to the research, development, and manufacturing of exosome-polymer hybrids (EPHs), a tether-based exosome functionalization strategy that enables Treg exosomes to be homed to proteins of interest, while delivering select payloads into those targeted cells. “This collaboration with Carnegie Mellon University further solidifies Coya’s thought leadership in the global exosome therapeutics field, beyond Treg-derived exosomes alone,” stated Howard Berman, PhD, CEO of Coya Therapeutics. “Nanoengineering exosomes with such manufacturing efficiency to produce EPHs that can be customized to any surface protein, delivering growth factors or drugs, while enhancing cellular uptake and bioactivity is the future of targeted therapies.”